TGFB1 and pulmonary fibrosis: In brief, the results of this study showed for the first time that PFD is a potent inhibitor of human TGFβ1-driven lung fibrosis in vivo and that intrapulmonary delivery of low doses of PFD evokes therapeutic response equivalent to high doses of oral PFD.